Samsung Biologics Decides to Acquire Peptide CDMO PolyPeptide Group for Approximately 2.7 Trillion Won
Samsung Biologics has decided to acquire 33,016,411 common shares of Swiss-listed PolyPeptide Group AG via a tender offer at CHF 44.31 per share.
The total consideration is approximately 2.71 trillion KRW, representing 24.47% of total assets, and will be funded through internal cash and debt financing.
The acquisition aims to strengthen the peptide CDMO business, and an external valuation by Samjong KPMG confirmed the purchase price falls within a fair range of CHF 31.43 to CHF 63.22.
The transaction is conditional on a minimum tender of approximately 66.7% of the fully diluted shares, with the largest shareholder Draupnir Holding B.V. committing to tender its entire stake.
[AI Summary]Samsung Biologics enters the peptide CDMO space through a large-scale M&A worth approximately 2.7 trillion won. While no shareholder dilution occurs due to cash-debt funding, financial leverage is expected to increase. The price is deemed fair by external appraisal, but deal completion hinges on regulatory approvals and meeting the minimum tender condition.
KOSPI Filing Information
Report on Major Matters (Decision to Acquire Stocks and Investment Securities of Other Corporation)